文献速递水电解质与酸碱血液净化与透析

Patiromer减少血液透析终末期肾病患者高钾血症发作的随机试验

Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis.
PubMed 文献 · Kidney Int Rep · 2024-08-10

本研究为前瞻性随机开放标签试验,纳入33例每周三次血液透析的终末期肾病患者,1:1随机分为Patiromer组与常规治疗组。第4周Patiromer组血清钾≥5.5 mEq/l发作中位数显著低于对照组(0 vs. 3,P=0.024),但动态心电图所示显著心律失常事件组间无显著差异。

要点

  • 每日Patiromer可显著减少透析患者高钾血症发作频率。
  • 第4周Patiromer组高钾发作中位数0次,对照组3次。
  • 心律失常事件组间无显著差异,需更大样本验证。

核心结论

  • 每日Patiromer可降低每周三次血液透析的终末期肾病患者高钾血症发作频率。

研究设计与样本

  • 前瞻性随机开放标签试验,33例终末期肾病血液透析患者1:1随机分为Patiromer组与常规治疗组,31例纳入分析。

主要发现

  • 第4周Patiromer组血清钾≥5.5 mEq/l发作中位数显著低于对照组(0 vs. 3,P=0.024)。
  • 第4周动态心电图中6例出现>1000/24 h室性早搏,5例无持续性室性心动过速,3例房颤,1例心动过缓,组间无显著差异。

关键数值与推荐

  • Patiromer剂量根据第1、2、3周开始时血清钾浓度滴定。

临床怎么用

  • 对于血液透析的终末期肾病患者,每日Patiromer可作为减少高钾血症发作的干预选择。

局限性

  • 样本量小(33例随机,31例分析),为开放标签设计,随访仅4周,心律失常事件需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Individuals with end-stage kidney disease (ESKD) maintained on hemodialysis (HD) carry a high risk of cardiac arrhythmias. This risk is heightened by episodic hyperkalemia. The purpose of the study was to investigate whether patiromer administered daily reduced episodes of hyperkalemia in those with ESKD who receive HD, and to explore whether prescription of patiromer reduced the number of significant arrhythmia events. METHODS: This was a prospective, randomized, open-label trial. Eligible patients with ESKD on HD were identified. Participants were randomized 1:1 to patiromer versus usual care. Those randomized to patiromer were administered the medication daily, and the dose was titrated based on serum potassium concentrations at the start of weeks 1, 2, and 3. All participants received 7-day continuous cardiac monitors at baseline and at week 4. RESULTS: Of the 33 participants who were randomized, 1 withdrew due to adverse symptoms, and 1 withdrew due to pregnancy, leaving 31 in our analytic cohort. The mean age of randomized participants was 56 years, 55% were male, 81% were Black, and 10% were Hispanic/Latino. In week 4, the number of episodes of serum potassium ≥ 5.5 mEq/l was 13 in the patiromer group and 41 in the control group; with median number of episodes of hyperkalemia in the patiromer group significantly lower than that of control group (0 vs. 3, P = 0.024). In week 4 continuous cardiac monitors, 6 participants had > 1000/24 h premature ventricular contractions, 5 had no sustained ventricular tachycardia (VT), 3 had atrial fibrillation, and 1 had bradycardia, with no significant differences between the groups. CONCLUSION: Patiromer administered daily reduced the frequency of hyperkalemia in study participants with ESKD who receive thrice-weekly HD. Larger studies are needed to determine whether patiromer reduces significant cardiac events.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Middleton JP, Sun S, Murray S, et al. Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis. Kidney Int Rep. 2024. PMID: 39534190. doi:10.1016/j.ekir.2024.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。